SCHEMBL1482767

SCHEMBL1482767

COC(=O)c1ccc(COc2ncccc2-c2nc3cc(F)c(F)cc3n2Cc2cccc(Cl)c2)cc1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 8/20 0.45
TBXA2R P21731 7/20 0.45
MAPT P10636 4/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
TP53 P04637 1/20 0.40
KMT2A Q03164 1/20 0.39
RCE1 Q9Y256 1/20 0.39
PTGDR2 Q9Y5Y4 1/20 0.39
KDM4E B2RXH2 1/20 0.39
LMNA P02545 1/20 0.39
HPGD P15428 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
RORC P51449 1/20 0.39
GNRHR P30968 1/20 0.38
ALDH1A1 P00352 1/20 0.38
HTT P42858 1/20 0.38
PPARG P37231 1/20 0.38
THRB P10828 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1482479 0.93 DRD2 (0.47) DRD2TBXA2RMAPTSMN1; SMN2TP53
SCHEMBL1482614 0.91 RHEB (0.47) SMN1; SMN2KMT2ARCE1PTGDR2KDM4E
SCHEMBL1482532 0.89 TSHR (0.39) MAPTKMT2ARCE1PTGDR2GNRHR
SCHEMBL1482654 0.88 DCTPP1 (0.42) MAPTSMN1; SMN2TP53KMT2ARCE1
SCHEMBL1482809 0.87 DRD2 (0.49) DRD2TBXA2RMAPTSMN1; SMN2TP53
SCHEMBL1482947 0.86 S1PR1 (0.40) SMN1; SMN2KMT2ARCE1PTGDR2KDM4E
SCHEMBL1482308 0.84 RHEB (0.48) MAPTSMN1; SMN2TP53KMT2AKDM4E
SCHEMBL1482636 0.82 DRD2 (0.52) DRD2TBXA2RTP53KMT2A
SCHEMBL1482634 0.81 NR1H4 (0.42) MAPTSMN1; SMN2KMT2ARORCALDH1A1
SCHEMBL1482818 0.81 KMT2A (0.43) MAPTSMN1; SMN2TP53KMT2ARCE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8309581-B2 Benzimidazole derivatives HOFFMANN-LA ROCHE INC. (US) 2012-11-13 US disclosed
EP-2483247-A1 NEW BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS FXR AGONISTS F. Hoffmann-La Roche AG (CH) 2012-08-08 EP disclosed
WO-2011039130-A1 NEW BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS FXR AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2011-04-07 WO disclosed
US-20110077273-A1 NEW BENZIMIDAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2011-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110077273-A1 NEW BENZIMIDAZOLE DERIVATIVES BRI3BP, CYP3A4, RB1 DRD2 1464/4885TBXA2R 92/4885MAPT 3349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.